Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1427501

4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients

Provisionally accepted
Maria Gallardo Maria Gallardo 1*Marcos Cruces Marcos Cruces 2Yolanda Gómez Yolanda Gómez 3Constanza Fuenzalida Constanza Fuenzalida 2Javiera Silva Javiera Silva 4Laura A. Aravena Laura A. Aravena 1Eduardo Nuñez Eduardo Nuñez 1Aracelly Gaete Argel Aracelly Gaete Argel 4Elizabeth Rivas Elizabeth Rivas 1Alexis M. Kalergis Alexis M. Kalergis 5Ricardo Soto-Rifo Ricardo Soto-Rifo 4Fernando Valiente-Echeverría Fernando Valiente-Echeverría 4
  • 1 Universidad de Atacama, Copiapó, Chile
  • 2 Regional Hospital of Copiapó, Copiapó, III Atacama Region, Chile
  • 3 University of the Bío Bío, Concepción, VIII Biobío Region, Chile
  • 4 Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile
  • 5 Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Santiago Metropolitan Region (RM), Chile

The final, formatted version of the article will be published soon.

    Objective to evaluate the immune response to the SARS-CoV-2 vaccines in adults with immunemediated rheumatic diseases (IMRDs) in comparison to healthy individuals, observed 1-20 weeks following the fourth vaccine dose. Additionally, to evaluate the impact of immunosuppressive therapies, vaccination schedules, the time interval between vaccination and sample collection on the vaccine's immune response.We designed a longitudinal observational study conducted at the rheumatology department of Hospital de Copiapó. Neutralizing antibodies (Nabs) titers against the Wuhan and Omicron variant were analyzed between 1-20 weeks after administration of the fourth dose of the SARS-CoV-2 vaccine to 341 participants (218 IMRD patients and 123 healthy controls). 218 IMRD patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic vasculitis (VS) and systemic scleroderma (SS) were analyzed.

    Keywords: SARS-CoV-2, COVID-19 vaccines, Autoimmune rheumatic diseases, humoral IgG, immunosuppressive therapies. (Min.5-Max. 8

    Received: 13 May 2024; Accepted: 08 Jul 2024.

    Copyright: © 2024 Gallardo, Cruces, Gómez, Fuenzalida, Silva, Aravena, Nuñez, Gaete Argel, Rivas, Kalergis, Soto-Rifo and Valiente-Echeverría. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Maria Gallardo, Universidad de Atacama, Copiapó, Chile

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.